Across TCGA pan-cancer cohorts, OR5H2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR5H2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR5H2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5H2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, OV, and UCEC are the cancer types where OR5H2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.095	0.875	<.001	42	view →
OV	OS	Median	II,III,IV	0.118	0.844	<.001	36	view →
UCEC	DFS	Median	III,IV	1.000	0.536	.025	16	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OR5H2 tumor-vs-normal RNA expression · all OR5H2 data types